发布求助
文献互助 智能选刊 最新文献

Hepatic Oncology最新文献

筛选
英文 中文
Pathway of care of hepatocellular carcinoma in 2017. 2017 年肝细胞癌的护理路径。
IF 5
Hepatic Oncology Pub Date : 2016-10-01 Epub Date: 2017-06-21 DOI: 10.2217/hep-2017-0004
Federica Invernizzi, Massimo Colombo
{"title":"Pathway of care of hepatocellular carcinoma in 2017.","authors":"Federica Invernizzi, Massimo Colombo","doi":"10.2217/hep-2017-0004","DOIUrl":"10.2217/hep-2017-0004","url":null,"abstract":"","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 4","pages":"217-221"},"PeriodicalIF":5.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096445/pdf/hep-03-217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysregulated fatty acid metabolism in hepatocellular carcinoma. 肝细胞癌中脂肪酸代谢失调。
IF 5
Hepatic Oncology Pub Date : 2016-10-01 Epub Date: 2017-06-30 DOI: 10.2217/hep-2016-0012
Mingda Wang, Jun Han, Hao Xing, Han Zhang, Zhenli Li, Lei Liang, Chao Li, Shuyang Dai, Mengchao Wu, Feng Shen, Tian Yang
{"title":"Dysregulated fatty acid metabolism in hepatocellular carcinoma.","authors":"Mingda Wang,&nbsp;Jun Han,&nbsp;Hao Xing,&nbsp;Han Zhang,&nbsp;Zhenli Li,&nbsp;Lei Liang,&nbsp;Chao Li,&nbsp;Shuyang Dai,&nbsp;Mengchao Wu,&nbsp;Feng Shen,&nbsp;Tian Yang","doi":"10.2217/hep-2016-0012","DOIUrl":"https://doi.org/10.2217/hep-2016-0012","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most frequent and deadly malignancies worldwide. Studies are urgently needed on its molecular pathogenesis and biological characteristics. Dysregulation of fatty acid (FA) metabolism, in which aberrant activation of oncogenic signaling pathways alters the expression and activity of lipid-metabolizing enzymes, is an emerging hallmark of cancer cells, and it may be involved in HCC development and progression. The current review summarizes what is known about dysregulated FA metabolism in HCC and pathways through which this dysregulation may regulate HCC survival and growth. Our understanding of dysregulated FA metabolism and associated signaling pathways may contribute to the development of novel and efficient antitumor approaches for patients with HCC.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 4","pages":"241-251"},"PeriodicalIF":5.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 49
Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. 肝内胆管癌患者肝切除术后的监测结果。
IF 5
Hepatic Oncology Pub Date : 2016-10-01 Epub Date: 2017-01-20 DOI: 10.2217/hep-2016-0009
Amir A Rahnemai-Azar, Pallavi Pandey, Ihab Kamel, Timothy M Pawlik
{"title":"Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.","authors":"Amir A Rahnemai-Azar,&nbsp;Pallavi Pandey,&nbsp;Ihab Kamel,&nbsp;Timothy M Pawlik","doi":"10.2217/hep-2016-0009","DOIUrl":"https://doi.org/10.2217/hep-2016-0009","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (iCCA) is one of the fatal gastrointestinal cancers with increasing incidence and mortality. Although surgery offers the only potential for cure in iCCA patients, the prognosis is not optimal with low overall survival rate and high disease recurrence. Hence, adjuvant therapy is generally recommended in the management of high-risk patients. Identifying factors associated with disease recurrence and survival of the iCCA patients after resection will improve understanding of disease prognosis and help in selecting patients who will benefit from surgical resection or stratifying them for clinical trials. Despite development of new methods for early detection of tumor recurrence, effective prognostic models and nomograms, and recent advances in management, significant challenges remain in improving the prognosis of iCCA patients.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 4","pages":"223-239"},"PeriodicalIF":5.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36467811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Insights into the SIRFLOX study. SIRFLOX研究的见解。
IF 5
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-05-12 DOI: 10.2217/hep-2016-0006
Peter Gibbs
{"title":"Insights into the SIRFLOX study.","authors":"Peter Gibbs","doi":"10.2217/hep-2016-0006","DOIUrl":"https://doi.org/10.2217/hep-2016-0006","url":null,"abstract":"<p><p><b>Peter Gibbs speaks to Laura Dormer, Editorial Director:</b> Peter Gibbs is a medical oncologist at the Western and Royal Melbourne Western Hospitals (Australia), and a laboratory head at the Walter and Eliza Hall Institute (Australia). He has a particular interest in translational research related to prognostic and predictive biomarkers for colorectal cancer. He is also heavily involved in clinical research, including being lead investigator of multiple international Phase III trials. He leads several national and international cancer registries, capturing comprehensive treatment and outcome data for patients treated in routine clinical care.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"191-192"},"PeriodicalIF":5.0,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we? 从临床角度探讨肝细胞癌与免疫治疗我们在哪里?
IF 5
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-08-19 DOI: 10.2217/hep-2016-0008
Susanna V Ulahannan, Austin G Duffy
{"title":"Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?","authors":"Susanna V Ulahannan,&nbsp;Austin G Duffy","doi":"10.2217/hep-2016-0008","DOIUrl":"https://doi.org/10.2217/hep-2016-0008","url":null,"abstract":"The incidence of hepatocellular carcinoma (HCC) has been reported to continue to increase in the past decades [1], however, we and other groups have found that this might be changing in the USA [2,3]. In our study – based on SEER data – there seemed to be a plateau in incidence rate around 2007, and that the rate of diagnosis in patients with smaller tumors (<5 cm) surpassed larger tumors around 2005. Despite these positive findings, less than 25% of patients received potentially curative treatment with liver transplantation, resection or ablation. In patients who are not candidates for curative treatments, options are limited to transcatheter arterial chemoembolization (TACE) for intermediate stage disease and, in the advanced disease setting, systemic therapy with sorafenib, the only US FDA-approved drug treatment [4,5]. Recently, a Phase III trial reported that regorafenib in the second-line setting improved overall survival by 2.8 months (10.6 vs 7.8 months) when compared with placebo (HR: 0.62; p < 0.02) [6]. This was the first positive trial in many years and we will await further details from this study. There have been several Phase II and III trials attempting to improve the limited treatment options in HCC but unfortunately these trials have been negative [7]. Other Phase III trials that are ongoing in second-line setting include cabozantinib (NCT01908426), MET inhibitor tivantinib (NCT01755767) and the VEGFR2 inhibitor ramucirumab (NCT02435433). Thus there is an urgent need to find alternative durable and well-tolerated t reatments in HCC. There are many indications in the literature suggesting that HCC should be amenable to immune therapy. HCC has been reported to a cancer type where spontaneous tumor regressions are seen [8], although this is likely due to diverse mechanisms including either immune responses or vascular","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"183-185"},"PeriodicalIF":5.0,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Immune checkpoint inhibitors for hepatocellular carcinoma. 肝细胞癌的免疫检查点抑制剂。
IF 5
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-06-27 DOI: 10.2217/hep-2016-0004
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes
{"title":"Immune checkpoint inhibitors for hepatocellular carcinoma.","authors":"Christopher E Jensen,&nbsp;Arturo Loaiza-Bonilla,&nbsp;Paula A Bonilla-Reyes","doi":"10.2217/hep-2016-0004","DOIUrl":"https://doi.org/10.2217/hep-2016-0004","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and advanced HCC generally caries a poor prognosis. The treatment of advanced disease is limited to sorafenib, which provides only a limited improvement in survival, and novel therapies are, thus, sorely needed. Among emerging alternative approaches, immune checkpoint inhibitors are a particularly promising treatment modality. In this review, we summarize current knowledge of the mechanisms for the two primary targets of immune checkpoint inhibitors and discuss the relevance of these pathways to the immunology of HCC. We also review the state of ongoing and forthcoming trials of immune checkpoint blockade in HCC.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"201-211"},"PeriodicalIF":5.0,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 47
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients. Regorafenib和resce试验:肝细胞癌患者的新二线选择
IF 5
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-08-19 DOI: 10.2217/hep-2016-0007
Jordi Bruix
{"title":"Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients.","authors":"Jordi Bruix","doi":"10.2217/hep-2016-0007","DOIUrl":"https://doi.org/10.2217/hep-2016-0007","url":null,"abstract":"<p><p><b>Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director:</b> Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research Institute. His research has changed the diagnosis and treatment of liver cancer. Major highlights include: development of the BCLC staging and treatment; development of diagnostic criteria for hepatocellular carcinoma; identification of the value of portal pressure in predicting prognosis after resection; and acting as principal investigator of the Phase III trials that have shown the benefits of chemoembolization, sorafenib and regorafenib for patients with liver cancer. He has authored the European Assoaciation for the Study of the Liver, American Association for the Study of Liver Diseases and World Gastroenterology Organization Practice Guidelines and the United Network for Organ Sharing hepatocellular carcinoma (HCC) diagnostic criteria.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"187-189"},"PeriodicalIF":5.0,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. RFA联合溶热敏脂质体阿霉素:寻找治疗中等大小肝细胞癌的最佳方法。
IF 5
Hepatic Oncology Pub Date : 2016-08-01 Epub Date: 2016-06-10 DOI: 10.2217/hep-2016-0005
Riccardo Lencioni, Dania Cioni
{"title":"RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.","authors":"Riccardo Lencioni,&nbsp;Dania Cioni","doi":"10.2217/hep-2016-0005","DOIUrl":"https://doi.org/10.2217/hep-2016-0005","url":null,"abstract":"<p><p>When heated during a radiofrequency ablation (RFA) procedure to ≥40°C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95% CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 3","pages":"193-200"},"PeriodicalIF":5.0,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36469988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
What are the options for hepatocellular carcinoma patients who progress under sorafenib? 在索拉非尼治疗下进展的肝细胞癌患者有哪些选择?
IF 5
Hepatic Oncology Pub Date : 2016-04-01 Epub Date: 2016-03-23 DOI: 10.2217/hep-2016-0003
Eunice Y-T Lau, Terence K-W Lee
{"title":"What are the options for hepatocellular carcinoma patients who progress under sorafenib?","authors":"Eunice Y-T Lau,&nbsp;Terence K-W Lee","doi":"10.2217/hep-2016-0003","DOIUrl":"https://doi.org/10.2217/hep-2016-0003","url":null,"abstract":"Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hong Kong *Author for correspondence: Tel.: +852 3400 8799; Fax: +852 2364 9932; terence.kw.lee@polyu.edu.hk","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 2","pages":"105-108"},"PeriodicalIF":5.0,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2016-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36471087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes? 肝细胞癌经动脉治疗的进展:新技术会带来更好的结果吗?
IF 5
Hepatic Oncology Pub Date : 2016-04-01 Epub Date: 2016-03-23 DOI: 10.2217/hep-2015-0001
Thierry de Baere, Lambros Tselikas, Frederic Deschamps, Valerie Boige, Michel Ducreux, Antoine Hollebecque
{"title":"Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?","authors":"Thierry de Baere,&nbsp;Lambros Tselikas,&nbsp;Frederic Deschamps,&nbsp;Valerie Boige,&nbsp;Michel Ducreux,&nbsp;Antoine Hollebecque","doi":"10.2217/hep-2015-0001","DOIUrl":"https://doi.org/10.2217/hep-2015-0001","url":null,"abstract":"<p><p>Conventional transarterial chemoembolization (c-TACE) was validated in 2002 for intermediate stage hepatocellular carcinoma (HCC). Recent improvements in overall survival after c-TACE in HCC is linked to both better patient selection, and improvement in treatment technologies: catheter, image guidance and new drug delivery platforms. Drug eluting beads (DEBs) demonstrated a benefit over c-TACE in pharmacokinetic studies; however, two randomized studies comparing c-TACE and DEB-TACE demonstrated no benefit of DEB-TACE in response rate or overall survival. Delivery platforms loaded with yttrium-90 deliver selective internal radiation therapy, which opens a new field of therapy for HCC. Future improvement in intra-arterial therapies will include resorbable loadable embolic material, new emulsion used for c-TACE and platforms releasing multikinase inhibitors.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"3 2","pages":"109-118"},"PeriodicalIF":5.0,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2015-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36471088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信